Here comes the ranking of domestic listed instrument companies, Mindray first and United Imaging second.

Recently, www.instrument.com.cn released the TOP40 domestic listed instrument companies in 2022 by sorting out the annual performance of 40 domestic instrument companies in 2022. Among them, there are 15 companies involved in medical devices, respectively, Mindray Medical, United Imaging Medical, MGI, Edan  and so on.

1. Mindray Medical is far ahead, with revenue exceeding 30 billion yuan;

From the performance scale of major instrument companies, Mindray Medical is far ahead, with revenue exceeding 30 billion yuan; There are three companies with a scale between 5 and 10 billion, namely United Imaging, BGI and KHB; There are 4 companies with a scale between 2 and 5 billion, namely Autobio, MGI, Haierbio Medical and Meyer; There are a total of 2 companies with a scale between 1 and 2 billion, respectively, McAudy and Libon Instruments; A total of four companies are worth less than $1 billion.

From the perspective of performance growth, these 14 companies involved in medical devices all achieved performance growth in 2022. Among them, the fastest growth is KHB, which achieved a revenue of 6.97 billion yuan in 2022, an increase of 43.58% from 4.854 billion yuan in 2021.

The second fastest growing company, Haierbio Medical, achieved 2.864 billion yuan in 2022, an increase of 34.72% from 2.226 billion yuan in 2021; While TAILIN Bio, whose total revenue in 2022 was only 374 million yuan, ranked third in its growth rate, with revenue of 283 million yuan in 2021.

In addition, Mindray Medical, the big brother of domestic medical devices, achieved a 20.17% growth in revenue of 30.366 billion yuan in 2022; The domestic imaging giant United Imaging Medical achieved 9.238 billion yuan in 2022, an increase of 27.36% from 7.254 billion yuan in 2021.

02      Compared with foreign ranking, domestic instrument enterprises still have a gap

Previously, www.instrument.com.cn also released the “TOP Revenue Ranking of Global Listed instrument Companies in 2022”.

Looking at the financial reports of foreign instrument companies, Thermo Fisher ranked first with revenue of 44.92 billion dollars in 2022, Danaher ranked second with 31.47 billion dollars, while JEOL JEOL ranked 20th with annual revenue of 1.17 billion dollars, or 8.38 billion yuan. In China, only Sunny Optical, Mindray and Lianying Medical ranked 20th in terms of revenue. Among them, Sunny Optical is mainly engaged in the design, research and development, and sales of optics and optical related products.

Among the three main businesses of Mindray Medical, the revenue of Mindray Medical life information and support business reached 13.401 billion yuan; In vitro diagnosis business achieved revenue of 10.256 billion yuan; The medical imaging business achieved a revenue of 6.464 billion yuan. The instrument business is mainly concentrated in the IVD module, mainly in chemiluminescence, biochemistry, coagulation, large-layout blood cells and other products, and the overall proportion is still not high.

The nuclear magnetic resonance products of United Imaging Medical have reached the level of domestic substitution, but have little correlation with the laboratory analytical instrument market.

Therefore, whether it is medical devices or other scientific instruments, the current gap at home and abroad is still very large.

03 The state has issued a number of policies to support the development of the scientific instrument industry

In the past two years, supporting the development of domestic instruments has become the consensus of the government, the market and the public. Since the beggning of  first half of 2022, the central and local governments have invested more attention to domestic instruments, on the one hand, in the policy it encourages the priority procurement of domestic goods, strengthens the review and demonstration of imported product procurement; On the other hand, various places are also actively planning the development and manufacturing of high-end instruments and promoting the localization of scientific instruments.

In May 2022, the Ministry of Finance issued the Notice on Issues related to the Procurement Work of the Government Procurement Framework Agreement. It is worth noting that the notice makes it clear that the purchase of imported instruments requires approval.

In addition, Guangdong, Zhejiang, Anhui, Hubei, Sichuan and other provinces have also issued relevant policies as early as 2022 to clearly support the purchase of domestic instruments. At the same time, in terms of supporting increased research and development, many provinces and cities have also introduced relevant policies and measures.

Taking Anhui Province as an example, its “Anhui Province Implementation Measurement Development Plan (2021-2035) Work Plan” clearly proposes to support the quality improvement of high-end instrument industry. Specifically, encourage the core technology and core algorithm research of instruments and equipment, promote the quality improvement of general instruments such as chromatographs, mass spectrometers, scanning electron microscopes, magnetic resonance spectroscopy, specific surface and aperture analyzers, and cross-scale micro and nano topography measuring instruments, and gradually replace imports.

Article Source：House of instruments
 Data Source：www.instrument.com.cn

Translated & edited ： Bradyknows